NCT06186245

Brief Summary

Diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) are common, but serious metabolic disorders are often encountered in intensive care. In the intensive care setting, it is common to withhold food from patients during treatment of DKA. However, there is no evidence or current literature supporting this practice. The following proposed research investigates the initiation of an early diet versus withholding food during the treatment of diabetic ketoacidosis.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
200

participants targeted

Target at P50-P75 for not_applicable diabetes-mellitus

Timeline
Completed

Started Dec 2023

Typical duration for not_applicable diabetes-mellitus

Geographic Reach
1 country

1 active site

Status
enrolling by invitation

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

November 14, 2023

Completed
1 month until next milestone

Study Start

First participant enrolled

December 27, 2023

Completed
2 days until next milestone

First Posted

Study publicly available on registry

December 29, 2023

Completed
1.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2025

Completed
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2025

Completed
Last Updated

August 19, 2025

Status Verified

August 1, 2025

Enrollment Period

1.8 years

First QC Date

November 14, 2023

Last Update Submit

August 18, 2025

Conditions

Outcome Measures

Primary Outcomes (2)

  • Resolution of DKA

    Defined as a closed anion gap. Adjusted Anion Gap defined as (Blood Sodium - Blood Chloride - Blood Bicarbonate) + 0.25 x ((normal albumin (4.0)) x (observed albumin)); Elevated Anion Gap is \>12

    Typically resolution of DKA is 24-72 hours, may be up to 5 days in some patients

  • Length of stay in the medical intensive care unit (in days).

    The time from admission order is placed to the time the transfer to another unit order is placed

    Days (Typically 3-5 days in the MICU, may be up to 1 week).

Secondary Outcomes (2)

  • Length of stay in the hospital

    3-7 days, may be up to 1-2 weeks.

  • mortality

    30 day

Study Arms (2)

Early feeding

EXPERIMENTAL

If randomized to the experimental group, patient's diet will be advanced to clear liquid for the first day. On the second day, diet will be advanced to full liquid and advanced up to oral (carb controlled 1600 calories) diet as tolerated.

Other: Early feeding with an oral diet

Nothing per mouth

NO INTERVENTION

Patient will be kept without PO intake until they are bridged from the insulin drip

Interventions

Participants in the treatment arm will be initiated on a clear liquid diet on day 1 of medical ICU admission. Diet will be progressed on day 2 to full liquid diet or diabetic diet as patient tolerates based on which diet the patient would prefer.

Early feeding

Eligibility Criteria

Age18 Years - 89 Years
Sexall
Healthy VolunteersYes
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Males and females with the diagnosis of diabetic ketoacidosis (defined as blood glucose greater than 250 mg/dL, arterial pH less than 7.3, serum bicarbonate less than 15 mEq/L, and the presence of ketonemia or ketonuria)
  • Age between 18-89
  • Admission to the Medical Intensive Care Unit
  • Able to provide informed consent

You may not qualify if:

  • Pregnant and breast-feeding women
  • Institutionalized patients or prisoners
  • Patients unable to eat by mouth, including intubation, presence of any tube used for enteral feeding (nasogastric tube, orogastric tube, PEG tube, etc.), medical conditions requiring parenteral feeding, and a history of a medical condition that prevented oral intake prior to admission, including achalasia, esophageal cancer, stroke with residual deficits preventing oral intake, amyotrophic lateral sclerosis, or head and neck trauma.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Medical Center

Lubbock, Texas, 79415, United States

Location

MeSH Terms

Conditions

Diabetes MellitusDiabetic Ketoacidosis

Condition Hierarchy (Ancestors)

Glucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System DiseasesKetosisAcidosisAcid-Base ImbalanceDiabetes Complications

Study Officials

  • Kenneth Kenneth, MD

    Texas Tech University Health Science Center

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
SUPPORTIVE CARE
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

November 14, 2023

First Posted

December 29, 2023

Study Start

December 27, 2023

Primary Completion

November 1, 2025

Study Completion

December 1, 2025

Last Updated

August 19, 2025

Record last verified: 2025-08

Locations